Jasleen K. Randhawa

Statistics

Publications

Citations

368

H-Index

Active since

2014

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Princess Margaret Cancer Centre

Presbyterian Hospital

Fred Hutch Cancer Center

Ottawa Hospital

Jasleen K. Randhawa is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematologic malignancy therapy, and oncology.

Publications per year

2014–2023

Publications

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Jasleen K. Randhawa, Hagop M. Kantarjian, Gautam Borthakur et al. · Blood · 2014 · 115 citations

Medicine, Hematology, Oncology +13

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths et al. · The Lancet Haematology · 2023 · 85 citations

Medicine, Pharmacokinetics, Pharmacology +13

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant

Premal Lulla, Swati Naik, Spyridoula Vasileiou et al. · Blood · 2020 · 66 citations · Full text

Medicine, Hematology, Immunology +16

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes

May Daher, Juliana Elisa Hidalgo Lopez, Jasleen K. Randhawa et al. · American Journal of Hematology · 2017 · 27 citations · Full text

Medicine, Hematology, Pharmacology +16

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Michael R. Savona, James McCloskey, Elizabeth A. Griffiths et al. · Blood · 2020 · 21 citations · Full text

Medicine, Oncology, Pharmacology +12

1–5 of 9